3 completed, 1 enrolling by invitation, 1 recruiting. 2 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Enrolling by invitation 1 |
Follow Zevra Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA) Sodium phenylbutyrate - Combined D,L-2-hydroxyglutaric Aciduria | Phase 1 | Enrolling by invitation | Jerry Vockley, MD, PhD | 1 | 2025-07-30 | 2026-06-08 |
| Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) Sodium phenylbutyrate - Medium-chain Acyl-CoA Dehydrogenase Deficiency | Phase 2 | Recruiting | Jerry Vockley, MD, PhD | 24 | 2025-06-30 | 2026-10-21 |
| Study of SDX in Patients With Idiopathic Hypersomnia (IH) Serdexmethylphenidate, Placebo - Idiopathic Hypersomnia | Phase 2 | Completed | Zevra Therapeutics | 66 | 2022-12-28 | 2026-06-30 |
| KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD KP415 oral capsule - ADHD | Phase 3 | Completed | Zevra Therapeutics | 282 | 2018-03-13 | 2021-07-19 |
| KP415 Classroom Study in Children (6-12 Years of Age) With ADHD KP415 oral capsule, Placebo oral capsule - ADHD | Phase 3 | Completed | Zevra Therapeutics | 155 | 2017-12-20 | 2021-06-30 |
Attention Deficit Disorder with Hyperactivity (2) · Disorders of Excessive Somnolence (1) · Idiopathic Hypersomnia (1) · Medium chain acyl CoA dehydrogenase deficiency (1) · Mental Disorders (1) · Nervous System Diseases (1) · Sleep Wake Disorders (1)
4-phenylbutyric acid (2) · serdexmethylphenidate and dexmethylphenidate (2)
United States (5)
Gerard Vockley, MD, PhD (2) · Ann Childress, MD (1) · Christopher Drake, PhD (1) · Scott H Kollins, PhD (1)